CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical O
- 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG -- Promising Preliminary Efficacy and Safety Data from the Phase 1b...
Source: pharmiweb.com